⚠️ 本報告由 AI 根據公開資訊自動生成。內容可能存在疏漏或偏差，僅供參考。請在使用前自行核實資訊準確性。
AstraZeneca PLC
Healthcare | Drug Manufacturers - General
⚡ 報告撮要
📊 核心結論
AstraZeneca is a leading biopharmaceutical company with a strong focus on oncology and rare diseases, demonstrating consistent revenue growth and profitability. Its diverse product portfolio and robust R&D pipeline position it well in the global pharmaceutical market, though it faces patent expiration risks for some key drugs.
⚖️ 風險與回報
At its current price of US$184.74, AstraZeneca trades at a premium to some industry peers. The stock offers a potential upside to the average analyst target of US$223.79, reflecting confidence in its pipeline. However, regulatory hurdles and R&D setbacks pose downside risks, suggesting a balanced risk-reward profile for long-term investors.
🚀 為何AZN有望大升
- • Oncology pipeline advancements: Continued success in late-stage oncology trials could unlock significant new revenue streams and expand market share.
- • Emerging market expansion: Increased penetration in high-growth emerging markets could fuel accelerated revenue growth beyond established markets.
- • Strategic collaborations: Partnerships in key therapeutic areas, such as with Tempus and Pathos in oncology, could lead to innovative treatments and market leadership.
⚠️ 潛在風險
- • Patent cliff risks: Expiration of patents on major blockbuster drugs could lead to significant revenue loss due to generic competition.
- • Clinical trial failures: Setbacks in late-stage clinical trials for pipeline drugs could negatively impact future growth prospects and investor confidence.
- • Regulatory scrutiny: Increasing regulatory pressure on drug pricing and market access could compress margins and limit revenue potential.
🏢 公司概覽
💰 AZN的盈利模式
- • AstraZeneca discovers, develops, manufactures, and commercializes prescription medicines across several major therapeutic areas globally.
- • The company focuses on oncology (腫瘤學), cardiovascular (心血管), renal & metabolism (腎臟和代謝), respiratory & immunology (呼吸和免疫學), and rare diseases (罕見疾病).
- • Revenue is primarily driven by sales of its branded drugs through distributors and local representative offices worldwide.
收入結構
Oncology
45%
Medicines for various cancer types, a primary growth driver.
Cardiovascular, Renal & Metabolism
21%
Treatments for heart, kidney, and metabolic diseases.
Rare Disease
16%
Specialty medicines addressing rare and ultra-rare conditions.
Respiratory & Immunology
15%
Drugs for asthma, COPD, and autoimmune disorders.
Other
3%
Remaining product sales and miscellaneous revenue streams.
🎯 意義與重要性
AstraZeneca's diversified portfolio across critical therapeutic areas, particularly its strong oncology franchise, provides resilience against single-product dependencies and underpins long-term growth. This broad reach enables the company to address significant unmet medical needs globally.
⭐ 競爭優勢： AZN的獨特之處
1. Robust R&D Pipeline & Innovation
AstraZeneca has a deep and innovative research and development (研發) pipeline, consistently bringing new and improved treatments to market. This includes significant investment in novel drug discovery, evidenced by multiple ongoing clinical trials across its key therapeutic areas. This focus on innovation allows the company to develop differentiated products and maintain a competitive edge.
2. Strong Global Market Presence
The company has a significant global footprint, with sales generated across the Americas, Europe, Asia, Africa, and Australasia. This widespread market presence diversifies revenue streams and reduces dependence on any single region. Its established distribution networks and local representative offices provide strong market access and brand recognition worldwide.
3. Specialization in High-Growth Therapeutic Areas
AstraZeneca strategically focuses on therapeutic areas such as oncology and rare diseases, which typically command higher pricing power and offer substantial growth potential due to unmet medical needs. This specialization allows the company to allocate resources effectively and develop market-leading products in areas with favorable market dynamics and higher barriers to entry for competitors.
🎯 意義與重要性
These competitive advantages, particularly a strong R&D engine and strategic focus on high-growth areas, enable AstraZeneca to consistently deliver innovative medicines, sustain pricing power, and navigate an evolving healthcare landscape. This positions the company for continued growth and profitability.
👔 管理團隊
Pascal Claude Roland Soriot
CEO & Executive Director
Pascal Soriot, 66, has served as CEO (行政總裁) since 2012. He is credited with leading AstraZeneca through a period of significant transformation, including boosting its oncology franchise and navigating patent expirations. His strategic vision emphasizes R&D-driven growth and expanding into emerging markets, contributing to the company's strong pipeline and global presence.
⚔️ 競爭對手
The pharmaceutical (製藥) industry is highly competitive, characterized by intense research and development, patent protection, and stringent regulatory environments. AstraZeneca competes with large multinational pharmaceutical companies, as well as smaller biotech firms, across various therapeutic areas. Competition is based on drug efficacy, safety, price, and market access.
📊 市場背景
- 可觸及總市場（TAM） - The global pharmaceutical market is valued at over US$1.5 trillion, projected to reach US$2.5 trillion by 2033, driven by aging populations and medical innovation.
- 關鍵趨勢 - The increasing focus on precision medicine (精準醫學) and targeted therapies, particularly in oncology and rare diseases, is reshaping R&D strategies and market dynamics.
競爭者
簡介
與AZN對比
Pfizer
A multinational pharmaceutical and biotechnology corporation with a diversified portfolio spanning vaccines, oncology, and internal medicine.
Pfizer has a broader product range and a significant presence in vaccines, whereas AstraZeneca's recent growth has been strongly driven by its oncology and rare disease segments.
Merck & Co.
Known for its robust immuno-oncology franchise, particularly Keytruda, and a strong pipeline in vaccines and infectious diseases.
Merck's Keytruda directly competes with AstraZeneca's Imfinzi in the lucrative immuno-oncology market, creating intense rivalry in a key growth area.
Novartis
A Swiss multinational pharmaceutical company focused on innovative medicines, including gene therapies, and maintaining a strong oncology presence.
Novartis offers a diverse portfolio that overlaps with AstraZeneca in oncology and other therapeutic areas, emphasizing breakthrough therapies and advanced drug platforms.
📊 估值與分析
📈 華爾街總結
分析師評級分佈：1 持有, 7 買入, 2 強烈買入
1
7
2
12 個月目標價範圍
最低目標價
US$184
-0%
平均目標價
US$224
+21%
最高目標價
US$243
+32%
收市價: US$184.74 (1 May 2026)
🚀 利好情境 - 利好空間至 US$243
1. Oncology Pipeline Advancements
High機率
Continued success in late-stage oncology trials, like with Enhertu and Imfinzi, could lead to new approvals and significantly expand their market indications, driving substantial revenue growth towards the US$80 billion target by 2030.
2. Expansion in Rare Disease Segment
High機率
Continued development and successful commercialization of rare disease therapies, such as Ultomiris and Strensiq, offer high-margin revenue streams and address significant unmet medical needs, contributing to portfolio diversification and stability.
3. Emerging Market Penetration
Medium機率
Increased market penetration and expanded product access in rapidly growing emerging markets could provide a significant long-term growth engine, offsetting potential slowdowns in mature markets.
🐻 利淡情境 - 看涨空間至 US$184
1. Patent Expiration and Generic Competition
High機率
Looming patent expirations for key blockbuster drugs, such as Farxiga, could lead to significant revenue erosion due to the entry of lower-cost generic alternatives, impacting overall profitability and market share.
2. Clinical Trial Setbacks and Regulatory Hurdles
Medium機率
Failures in late-stage clinical trials or adverse regulatory decisions, as seen with Camizestrant and Tozorakimab, can delay product launches, incur substantial R&D costs, and negatively impact future revenue projections and investor confidence.
3. Increased Competition and Pricing Pressure
Medium機率
Intense competition from existing players and new entrants, coupled with global pressure to reduce medicine prices, could lead to pricing erosion and constrain revenue growth and operating margins.
🔮 結語：是否適合長線投資？
AstraZeneca's long-term appeal hinges on its ability to sustain its innovation engine and effectively commercialize its pipeline, particularly in oncology and rare diseases, while navigating patent expirations. Its global reach and strategic focus on high-growth therapeutic areas provide a durable foundation. However, the inherent risks of drug development, regulatory challenges, and competitive pressures are constant. Investors should be confident in management's continued ability to execute on its US$80 billion revenue target by 2030 and adapt to evolving healthcare demands.
📋 附錄
財務表現
指標
31 Dec 2025
31 Dec 2024
31 Dec 2023
損益表
收入
US$58.74B
US$54.07B
US$45.81B
毛利
US$48.11B
US$43.87B
US$37.54B
營業收入
US$13.33B
US$10.25B
US$8.72B
淨收入
US$10.22B
US$7.04B
US$5.96B
每股盈利（攤薄）
6.54
4.50
3.81
資產負債表
現金及等價物
US$5.71B
US$5.49B
US$5.84B
總資產
US$114.07B
US$104.03B
US$101.12B
總負債
US$29.15B
US$30.11B
US$28.41B
股東權益
US$48.67B
US$40.79B
US$39.14B
主要比率
毛利率
81.9%
81.1%
82.0%
營業利潤率
22.7%
19.0%
19.0%
Return on Equity
21.01
17.25
15.21
分析師預估
指標
Annual (31 Dec 2026)
Annual (31 Dec 2027)
每股盈利預估
US$6.78
US$8.71
每股盈利增長
+48.0%
+28.5%
收入預估
US$63.4B
US$67.3B
收入增長
+7.9%
+6.1%
分析師數量
3
4
估值比率
| 指標 | 數值 | 簡介 |
|---|---|---|
| P/E Ratio (TTM) | 27.86 | The Price-to-Earnings ratio (TTM) compares the current share price to the company's earnings per share over the trailing twelve months, indicating how much investors are willing to pay for each dollar of earnings. |
| Forward P/E | 23.72 | The Forward Price-to-Earnings ratio uses estimated future earnings to provide a forward-looking valuation, reflecting market expectations for future profitability. |
| PEG Ratio | 1.53 | The Price/Earnings-to-Growth (PEG) ratio adjusts the P/E ratio for expected earnings growth, offering a more complete picture for growth companies by indicating if the P/E is high due to high growth. |
| Price/Sales (TTM) | 4.74 | The Price-to-Sales ratio (TTM) measures the stock price relative to the company's revenue over the trailing twelve months, often used for valuing growth companies or those with inconsistent earnings. |
| Price/Book (MRQ) | 6.05 | The Price-to-Book ratio (MRQ) compares the market value of a company to its book value, indicating how much investors are willing to pay for each dollar of net assets on the balance sheet. |
| EV/EBITDA | 15.63 | The Enterprise Value to EBITDA ratio is a valuation multiple that compares the total value of a company (including debt) to its earnings before interest, taxes, depreciation, and amortization, useful for comparing companies with different capital structures. |
| Return on Equity (TTM) | 0.23 | Return on Equity (TTM) measures the net income generated for each dollar of shareholders' equity over the trailing twelve months, indicating how efficiently a company is using shareholder investments to generate profits. |
| Operating Margin | 0.28 | Operating Margin indicates the percentage of revenue left after covering operating costs, reflecting a company's core profitability from its primary business operations. |
同業比較
| 公司 | 市值（十億） | 市盈率 | 市帳率 | 收入增長（%） | 營業利潤率（%） |
|---|---|---|---|---|---|
| AstraZeneca PLC (Target) | 286.40 | 27.86 | 6.05 | 12.5% | 28.2% |
| Pfizer | 152.72 | 19.36 | 1.75 | -1.6% | 12.0% |
| Merck & Co. | 274.00 | 14.80 | 5.34 | 4.9% | 32.4% |
| Novartis | 298.60 | 20.52 | 5.86 | 9.6% | 28.9% |
| 行業平均 | — | 20.64 | 4.75 | 6.3% | 25.4% |